Hyperemesis Gravidarum Therapy

Patient Information

Patient Name:		SSN:	Age:
Address:		Gender:	DOB:
City, State:	Zip:	Phone:	Language:
Caregiver Name:		Relationship:	Phone:
Emergency Contact:		Relationship:	Phone:

Primary Insurance:		**Secondary Insurance:**	
Subscriber:		Subscriber:	
Policy #:	Group #:	Policy #:	Group #:
Insurance Phone:		Insurance Phone:	

Statement of Medical Necessity (please provide all information)

Primary Diagnosis: ☐ 021.1 - Hyperemesis gravidarum with metabolic disturbances is 021.1
☐ Other: ICD-10: __________ Description: ______________________________

Medical History: ☐ Diabetes ☐ Peptic Ulcer Disease ☐ Immunodeficiency ☐ Cardiac Disease ☐ Other:

Allergies: ☐ NKDA or List in space below:	Pre-pregnancy Wt: ☐ lbs ☐ kg Date:
	Pre-illness Wt: ☐ lbs ☐ kg Date:
G/P: EDC: Height:	Current Wt: ☐ lbs ☐ kg Date:

Did patient receive other medical therapies within the last 6 months? ☐ Yes ☐ No If yes, Date:

Current Medications: Attach to the patient's current medication profile

Prescription (please check all that apply)

☐ Intravenous hydration	☐ Fluid type: _____ ☐ Rate of infusion: _____ ☐ Duration of therapy: _____ Medications: _____
☐ Metclopramide **(Reglan®)**	☐ 10 mg IV or IM initially, followed by mg per hour continuous Subcutaneous infusion, may titrate up to mg/hour for symptom control (average effective dose 1.28 mg/hour). ☐ Other regimen:
☐ Ondansetron **(Zofran®)**	Intermittent: ☐ 2 mg ☐ 4 mg IV every 6 - 8 hours Continuous: ☐ Titrate per patients response between mg and mg (Usual dosing 12 - 32 mg) per day ☐ IV ☐ Subcutaneous continuously via pump. Bolus: ☐ mg (1 - 4 mg) demand dose allowed every hours, times doses. (Max demand dose is 4 mg per day)
☐ Parenteral Nutrition	Dietitian to assess patient and provide PN formula recommendations
☐ Other:	

Is this the first dose? ☐ Yes ☐ No If No, date first dose given: ☐ Start ASAP ☐ Date of last dose:

Orders (please check all that apply)

TEACHING: Instruct patient/caregiver about all aspects of their therapy and the s/s of complications.

NURSING VISITS: Nurse to assess patient for status and response signs and symptoms every .
TB status: ☐ Active TB ☐ PPD (-) date: ☐ Last CXR date: ☐ Unknown DNR status: ☐ Rc'd ☐ N/A

Access: ☐ Subcutaneous ☐ Peripheral ☐ Midline ☐ PICC ☐ Other:

Catheter Maintenance: ☐ Option Care Health Infusion Protocol ☐ Other:

Labs: ☐ CBC w/ Differential ☐ Albumin ☐ LFT ☐ Chem-7 ☐ Urine specific gravity ☐ Urine ketones ☐ Other:
Frequency: ☐ Weekly ☐ Other:

Other Orders:
☐ Follow up with Prescriber scheduled for:
☐ Option Care Health to follow patient progress including weight (patient to monitor every morning).

If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatment, and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.

I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.

Prescriber Signature: Date:

Prescriber Information

Prescriber Name:	Phone:	Fax:	Office Contact:
Address:		Hospital/Clinic:	NPI:
City, State:	Zip:	License:	UPIN:

Fax completed form, insurance information, and clinical documentation to:

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. **IMPORTANT WARNING**: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.

Not valid for use for patients residing in Arizona, New York, and Wisconsin.

 ©2026 All rights reserved.